Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon575 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A11520 | 30861258 | Hepatol Res | Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. | 2019 | Details |
| A11551 | 30847736 | Curr Obes Rep | Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery. | 2019 | Details |
| A11553 | 30844893 | Curr Opin Gastroenterol | Current treatment options for nonalcoholic fatty liver disease. | 2019 | Details |
| A11557 | 30841472 | Biomed Pharmacother | Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. | 2019 | Details |
| A11611 | 30820265 | World J Hepatol | Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. | 2019 | Details |
| A11679 | 30792450 | Sci Rep | Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. | 2019 | Details |
| A11779 | 30747091 | Curr Mol Pharmacol | Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone. | 2019 | Details |
| A11818 | 30721572 | Liver Int | Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. | 2019 | Details |
| A11867 | 30703836 | Dtsch Med Wochenschr | [The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy]. | 2019 | Details |
| A12000 | 30652641 | Curr Pharm Des | Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. | 2018 | Details |
| A12040 | 30628563 | Proc Nutr Soc | Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. | 2019 | Details |
| A12091 | 30605949 | Zhonghua Nei Ke Za Zhi | [Glucagon-like peptide-1 regulates lipid metabolism in hepatocytes through Foxo1/3]. | 2019 | Details |
| A12095 | 30605011 | Am J Physiol Gastrointest Liver Physiol | Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. | 2019 | Details |
| A12156 | 30578967 | Biochim Biophys Acta Mol Cell Biol Lipids | Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. | 2018 | Details |
| A12223 | 30556145 | Hepatology | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12285 | 30533179 | World J Hepatol | Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? | 2018 | Details |
| A12313 | 30502373 | Metabolism | Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. | 2018 | Details |
| A12335 | 30510243 | Exp Mol Med | Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. | 2018 | Details |
| A12423 | 30459715 | Front Endocrinol (Lausanne) | Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. | 2018 | Details |
| A12487 | 30428692 | Diab Vasc Dis Res | Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. | 2018 | Details |
| A12514 | 30413050 | Pharmaceuticals (Basel) | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? | 2018 | Details |
| A12534 | 30405191 | Sci Rep | Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. | 2018 | Details |
| A12535 | 30404689 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | [Nonalcoholic Fatty Liver Disease and Weight Loss]. | 2018 | Details |
| A12625 | 30360555 | Nutrients | Cafeteria Diet Feeding in Young Rats Leads to Hepatic Steatosis and Increased Gluconeogenesis under Fatty Acids and Glucagon Influence. | 2018 | Details |
| A12630 | 30359962 | Pharmacol Res | Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 2018 | Details |
| A12631 | 30359371 | PLoS One | N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice. | 2018 | Details |
| A12690 | 30325900 | Med Sci Monit | Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A12758 | 30299993 | Expert Opin Pharmacother | Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. | 2018 | Details |
| A12767 | 30297626 | Int J Mol Sci | Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. | 2018 | Details |
| A12801 | 30282916 | Diseases | Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. | 2018 | Details |
| A12819 | 30269815 | Biochem Biophys Res Commun | Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. | 2018 | Details |
| A12863 | 30250238 | Sci Rep | Human hepatic 3D spheroids as a model for steatosis and insulin resistance. | 2018 | Details |
| A12963 | 30206707 | Amino Acids | Regulation of glucose and lipid metabolism by the pancreatic and extra-pancreatic actions of taurine. | 2018 | Details |
| A13075 | 30149145 | Diabetes Metab | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. | 2018 | Details |
| A13210 | 30081580 | Nutrients | Paeoniflorin Ameliorates Fructose-Induced Insulin Resistance and Hepatic Steatosis by Activating LKB1/AMPK and AKT Pathways. | 2018 | Details |
| A13230 | 30073766 | Diabetes Obes Metab | Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. | 2018 | Details |
| A13250 | 30064623 | Ugeskr Laeger | [Treatment of non-alcoholic fatty liver disease]. | 2018 | Details |
| A13280 | 30052880 | Endocrinology | GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice. | 2018 | Details |
| A13487 | 29953740 | Basic Clin Pharmacol Toxicol | Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis. | 2018 | Details |
| A13488 | 29953011 | Medicine (Baltimore) | Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. | 2018 | Details |
| A13540 | 29924135 | Braz J Med Biol Res | Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. | 2018 | Details |
| A13622 | 29869810 | Diabet Med | Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. | 2018 | Details |
| A13641 | 29859019 | Br J Pharmacol | A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. | 2018 | Details |
| A13683 | 29808958 | Clin Physiol Funct Imaging | Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. | 2018 | Details |
| A13698 | 29802679 | J Diabetes Investig | Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis. | 2018 | Details |
| A13756 | 29772784 | Nutrients | Capsaicin in Metabolic Syndrome. | 2018 | Details |
| A14080 | 29600430 | Hepatol Int | Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. | 2018 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14425 | 29412830 | Peptides | Glucagon receptor signaling in metabolic diseases. | 2018 | Details |
| A14438 | 29406832 | Can J Physiol Pharmacol | Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. | 2018 | Details |
| A14469 | 29398867 | World J Gastroenterol | Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. | 2018 | Details |
| A14513 | 29375204 | World J Gastroenterol | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. | 2018 | Details |
| A14539 | 29363040 | Drugs | Semaglutide: First Global Approval. | 2018 | Details |
| A14552 | 29357809 | Cardiovasc Hematol Agents Med Chem | Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A14576 | 29344336 | Ther Adv Endocrinol Metab | Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. | 2017 | Details |
| A14668 | 29295869 | Endocr Connect | Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial. | 2018 | Details |
| A15078 | 29107284 | Mol Metab | Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. | 2017 | Details |
| A15083 | 29104811 | Liver Res | Bile acid metabolism and signaling in liver disease and therapy. | 2017 | Details |
| A15162 | 29066788 | Sci Rep | Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. | 2017 | Details |
| A15291 | 28983453 | Curr Pharmacol Rep | Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. | 2017 | Details |
| A15311 | 28971838 | Am J Physiol Gastrointest Liver Physiol | Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. | 2017 | Details |
| A15407 | 28926951 | Nutrients | Insights into the Hexose Liver Metabolism-Glucose versus Fructose. | 2017 | Details |
| A15424 | 28919478 | Biochim Biophys Acta Mol Cell Biol Lipids | Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. | 2017 | Details |
| A15429 | 28918389 | J Investig Med | Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. | 2017 | Details |
| A15501 | 28874313 | Gastroenterol Hepatol | New therapeutic perspectives in non-alcoholic steatohepatitis. | 2017 | Details |
| A15528 | 28859855 | Gastroenterology | Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. | 2017 | Details |
| A15631 | 28799803 | Crit Rev Food Sci Nutr | Nutrition, inflammation and liver-spleen axis. | 2017 | Details |
| A15682 | 28763870 | Zhonghua Gan Zang Bing Za Zhi | [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances]. | 2017 | Details |
| A15812 | 28696785 | Arch Physiol Biochem | Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model. | 2017 | Details |
| A15850 | 28681988 | Diabetes Obes Metab | Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. | 2017 | Details |
| A15862 | 28677333 | Aliment Pharmacol Ther | Review article: new treatments in non-alcoholic fatty liver disease. | 2017 | Details |
| A15871 | 28676027 | Curr Vasc Pharmacol | The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options? | 2018 | Details |
| A15966 | 28635324 | Antioxid Redox Signal | Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis. | 2017 | Details |
| A15968 | 28634585 | J Diabetes Res | High Plasma Glucagon Levels Correlate with Waist-to-Hip Ratio, Suprailiac Skinfold Thickness, and Deep Subcutaneous Abdominal and Intraperitoneal Adipose Tissue Depots in Nonobese Asian Indian Males with Type 2 Diabetes in North India. | 2017 | Details |
| A16121 | 28552096 | Dan Med J | The role of incretin hormones and glucagon in patients with liver disease. | 2017 | Details |
| A16216 | 28503750 | Diabetes Obes Metab | Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. | 2017 | Details |
| A16267 | 28478385 | J Biol Chem | Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. | 2017 | Details |
| A16371 | 28431668 | Diabetes Metab | GLP-1 receptor agonists in NAFLD. | 2017 | Details |
| A16377 | 28428362 | J Endocrinol | Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. | 2017 | Details |
| A16503 | 28349245 | J Gastroenterol | Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. | 2017 | Details |
| A16515 | 28346237 | Curr Opin Gastroenterol | Current and future pharmacologic treatment of nonalcoholic steatohepatitis. | 2017 | Details |
| A16554 | 28319060 | Oncogene | The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. | 2017 | Details |
| A16613 | 28283346 | Eur J Intern Med | Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes? | 2017 | Details |
| A16632 | 28274625 | Eur J Pharmacol | APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice. | 2017 | Details |
| A16681 | 28249273 | Dig Dis | Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. | 2017 | Details |
| A16979 | 28065744 | Clin Res Hepatol Gastroenterol | Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2017 | Details |
| A16987 | 28062946 | J Gastroenterol | Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17004 | 28052626 | Liver Int | Therapies in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17028 | 30802390 | Klin Lab Diagn | [The phylogenetic theory of general pathology. The development of seven biological functions, seven specific ones and etiological factors of metabolic epidemics, millions years' common pathogenesis and basics of prevention.] | 2019 | Details |
| A17056 | 28019064 | Hepatol Res | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. | 2017 | Details |
| A17111 | 27986466 | Trends Endocrinol Metab | Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. | 2016 | Details |
| A17135 | 27973438 | Int J Mol Sci | Pathophysiology of Non Alcoholic Fatty Liver Disease. | 2016 | Details |
| A17198 | 27917557 | Hepatol Res | Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. | 2016 | Details |
| A17201 | 27916783 | Endocr J | Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. | 2016 | Details |
| A17264 | 27880981 | Hepatology | A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. | 2017 | Details |
| A17386 | 27810989 | Diabetes Care | Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. | 2016 | Details |
| A17495 | 27720451 | Cell | Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. | 2016 | Details |
| A17545 | 27611762 | Biomark Med | The biology of glucagon and the consequences of hyperglucagonemia. | 2016 | Details |
| A17740 | 27627981 | Diabetologia | Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. | 2016 | Details |
| A17814 | 27564402 | Expert Opin Pharmacother | Emerging and future therapies for nonalcoholic steatohepatitis in adults. | 2016 | Details |